anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study is a randomized, double-blind, multicenter, parallel group, placebo-controlled trial of oral enoximone in approximately 700 subjects with advanced chronic heart failure of either ischemic or nonischemic etiology receiving optimal conventional heart failure therapy.

Eligible subjects will be randomized in a 1:1 ratio to receive either enoximone or placebo at the Randomization Visit. The initial dose of study drug will be 25 mg t.i.d.(3xday) and will be administered immediately after randomization. Subjects who tolerate this initial dose will be continued on 25 mg t.i.d. for at least two weeks. After two weeks, eligible subjects will be titrated to 50 mg t.i.d. for the duration of the study.
<P>PROBLEM TO BE SOLVED: To provide a prenyl derivative compound having an inhibitory effect against NO production, and an anti-inflammatory agent containing the same.  <P>SOLUTION: The new compound is the prenyl derivative compound of formula (I) (wherein Het is a heterocyclic group of formula (II), (III) or (IV)). The compound can be prepared through a known process using as a starting material a compound obtained by the extraction of the root of Ferula fukanensis K M shen with an organic solvent (e.g. methanol, chloroform or ethyl acetate). The compound has an inhibitory effect against NO production and is useful as an anti-inflammatory agent or an antiallergic agent.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Participants randomized to BfitBwell + PA behavior change counseling sessions will receive six, 1-1.5 hour sessions lead by a Certified Exercise Physiologist, trained on the study protocol. Sessions will be held once per week, every other week at the Anschutz Health and Wellness center. Participants will attend the sessions in groups, as schedules allow. Behavior change discussion topics will target self-efficacy for exercise, barriers to exercise, goal setting, behavior modification strategies, time management, cognitive reframing, and relapse prevention. Participants in this study arm will receive a group education workbook in congruence to discussion session topics to promote notetaking, and self-reflective journaling.
PCT No. PCT/US94/12351 Sec. 371 Date May 2, 1996 Sec. 102(e) Date May 2, 1996 PCT Filed Nov. 3, 1994 PCT Pub. No. WO95/12385 PCT Pub. Date May 11, 1995A pharmaceutical composition comprises microparticles in micelle. The microparticles contain at least one pharmaceutically-active agent, at least one water soluble or miscible phospholipid, at least one lipid soluble or miscible phospholipid, at least one non-ionic surfactant having an HLB value of about 15 or greater, at least one non-ionic surfactant having an HLB value of about or less, and at least one water soluble or miscible sterol compound. The microparticles are suspended in at least one fatty acid having a chain length of C14 or less. The composition may optionally contain at least one fatty acid having a chain length of C16 or greater in a concentration of about 5 w/v % or less. The composition is prepared by admixing the pharmaceutically-active agent, phospholipids, surfactants, and sterol, micronizing the admixture to form microparticles, and suspending the microparticles in at least one fatty acid of chain length of C14 or less to form microparticles in micelle. The invention may be useful in the oral administration of drugs and other therapeutic agents, as well as for the trans-umbilico-dermal administration of such drugs and therapeutic agents.
PURPOSE: A composition containing a Pelargonium extract is provided to prevent crystallization by reducing the content of alcohol of a final composition, thereby improving formulation stability. CONSTITUTION: A pharmaceutical composition contains a Pelargonium extract and sorbic acid or a salt thereof. The final composition of the pharmaceutical composition contains alcohol in a content of 1.0 wt% or less. The extract is prepared from Pelargonium Sidoides, Pelargonium Reniforme, or a mixture thereof using a solvent selected among water, ethanol, propanol, butanol, and a mixture thereof. The pharmaceutical composition additionally contains tartaric acid as a pH adjusting agent. [Reference numerals] (AA) Example 1- Stationary sate at room temperature (14 days,25 °C); (BB) Example 1- refrigerate stationary sate (7 days, 4°C); (CC) Example 21- Stationary sate at room temperature (14 days, 25°C); (DD) Example 21- refrigerate stationary sate (14 days, 4°C)
PURPOSE:A cholesterol reducing agent, prepared by adding a mixture of vegetable sterol with a compound selected from a triterpenic alcohol to an animal fat or oil, and capable of exhibiting a very great reducing effect on the cholesterol in a small amount without causing problems in storing food nor taste. CONSTITUTION:A mixture of vegetable sterol contained in soybean seeds, coconuts or cotton seeds, with a triterpenic alcohol, e.g. cycloartenol, 2,4-methylenecycloartanol and cyclolaudenol, is added to an animal fat or oil or a food containing it, e.g. mayonnaise or dressing, etc. The triterpenic alcohol is contained in rice bran, soybean oil, etc., and commercially available gamma-oryzanol is saponified conveniently to prepare the aimed triterpenic alcohol from the unsaponified compound. The mixing ratio of the vegetable sterol to the triterpenic alcohol in the mixture is as follows: 100pts.wt. vegetable sterol and 1-20pts.wt., preferably about 5pts.wt., triterpenic alcohol.
The invention relates to a single heavy chain variable domain antibody (VHH) that binds Ece1p, and/or a peptide derived therefrom, from C. albicans. The invention further relates to VHH that recognize cell wall proteins of C. albicans hyphae, such as Als3p. The invention further relates to a bi- or multi-specific antibody comprising such VHH and to mono- or bispecific antibody comprising such VHH fused on gene level to the Fc part of human antibodies and to methods and means for producing such VHH. The invention further relates to an antibody of the invention, for use in diagnostic applications and for use as a medicament. The invention further relates to single heavy chain variable domain antibodies that bind to adhesins of C. albicans and related pathogenic fungi. The invention further relates to an antibody of the invention, for use in diagnostic applications or for use as a medicament. The invention further relates to a microbicide comprising an antibody of the invention, and to a pharmaceutical composition comprising an antibody of the invention. Finally the invention relates to food grade lactic acid bacteria that express VHH against Ece1p or adhesins.
CRPS patients that will be examined for trigger points in the thoracic muscles. 10 out of the 23 will also be included in the intervention stage and will recieve a month of conventional physiotherapy, and a month of conventional physiotherapy with addition of massage to the thoracic area.
In arm 2, participants will attend the risk communication session utilising AI module (PERDICT.AI) without PTEC-DM. Screen activity of PERDICT.AI will be recorded using a screen capture software. The entire session will be audio recorded.
Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
Adult participants who are engaged in the Centers for Disease Control and Prevention's (CDC) National Diabetes Prevention Program lifestyle intervention (DPP) as delivered by the Johns Hopkins Brancati Center; this is a 12-month long, group-based lifestyle intervention, delivered by a certified lifestyle coach using a CDC-approved curriculum. This "concurrent control" group will consist of adults who are enrolled in the Brancati Center's DPP within 6 months of the intervention group start dates, who have children less than 18 years of age living in their households.
Patients with hypothermia (\<36C) will be warmed by air blown underbody blanket before the surgical procedure. Warming procedure will be continued during and postoperative 2 hours of surgery. Body temperature will be measured by tympanic temperature gauge. Intravenous fluid, antiseptic solutions and irrigation fluids will be given to the patients during surgery by heating before administering. Body temperature, blood pressure, respiratory rate, heart rate and O2 saturation of the patients will be monitored every 15 minutes during the operation and postoperative 2 hours and data will be recorded on the data collection form.
PURPOSE:To easily emulsify a highly hydrophobic compd. by compounding specified alpha-sulfo fatty acid ester, higher alcohol, oil component and water each by specified amt. to prepare an oil-in-water emulsion composite. CONSTITUTION:alpha-sulfo fatty acid ester or its salt (A) expressed by formula I, higher alcohol (B), oil component (C) and water (D) are mixed under shearing agitation by use of a homogenizer, etc., to prepare the oil-in-water emulsion composition. In the formula I, R1 and R2 represent alkyl groups or alkenyl groups of 6-25 carbon number, and M is hydrogen atom, alkali metal atom, ammonium residual group, or alkaline earth metal by the amt. corresponding to univalent atom. The weight ratio of B to A is <=1, and the weight ratio of C to the sum of A and B is <=300. The oil component is, for example, hydrophobic oil such as vegetable or animal oil and wax.
Study numbers will be randomized into "standard-dose saproterin" or "high-dose saproterin" groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Goal high-dose saproterin dihydrochloride dosing will be 40mg/kg (rounded up to the nearest 500mg), provided in the form of pre-packaged 500mg packets of powder. Labeled dosing on these packets will be covered by the investigational drug pharmacy and unidentifiable to patients. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily.
Postsurgical thyroid remnant ablation with (131)I is considered standard clinical care for most cases of papillary and follicular thyroid cancer, to eliminate normal thyroid tissue which may contain microscopic cancer. Furthermore, ablation enhances the sensitivity of subsequent (131)I scanning and serum thyroglobulin (TG) measurement for the detection of recurrent or persistent disease. Low dose (131)I (30 mCi) successfully ablates thyroid remnant in 8-61% of cases. This dose can be repeated and result in overall less radiation exposure than that associated with high dose therapy (100 mCi). Ablation achieved with one or more small doses of radioactive iodine is not associated with decreased survival or cancer recurrence. According to the literature there is no difference in the 30-year recurrence rates between groups receiving low and high dose ablation therapy for well differentiated thyroid cancer without distant metastases at the time of initial therapy. The benefits of using low dose of (131)I are minimization of whole body radiation exposure, reduction in side effects and lower cost. Higher rates of successful ablation by low dose of 131I could be achieved by increasing uptake of (131)I and/or lengthening retention of radioiodine in the remnant thyroid tissue. Recombinant human thyroid-stimulating hormone (rhTSH) has been used successfully to increase radioiodine uptake. Lithium has been used to increase radioiodine retention and has been shown to be useful in the treatment of residual or metastatic cancer. The combination of rhTSH and lithium as adjuncts to 30 mCi radioactive iodine (RAI) ablation therapy in low risk thyroid cancer patients may provide a method that reduces the cumulative dose of radioiodine needed to successfully treat thyroid cancer. The specific aim of this study is to determine whether adjunct lithium carbonate improves the success rate of postsurgical ablation of thyroid remnants using low dose (131)I (30 mCi) and rhTSH in low risk patients with differentiated thyroid carcinoma. Patients with well-differentiated papillary or follicular thyroid cancer stage I or II, according to the National Thyroid Cancer Treatment Cooperative Study (NTCTCS) classification at time of surgery, will be enrolled. Eligible patients will have had a total or near-total thyroidectomy within 6 months of enrollment. This randomized, placebocontrolled, double-blind study will permit an evaluation of the risk/benefit ratio of adding lithium as an adjuvant to the already established method of administering low-dose (131)I ablation therapy, to optimize the (131)I retention. All patients will undergo diagnostic rhTSH (123)I whole body scan at the end of the study to assess the success of thyroid ablation.
The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
Before medication, TPMT activity was normal, and azathioprine was started at small doses and added every two weeks after no adverse effects, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid. Low-dose hormone therapy was administered to all patients simultaneously.Blood (5ml) was collected from peripheral veins in 6 months after AZA treatment.
INTRODUCTION: The relationship between brain lesions and stroke outcomes is crucial for advancing patient prognosis and developing effective therapies. Stroke is a leading cause of disability worldwide, and it is important to understand the neurological basis of its varied symptomatology. Lesion-symptom mapping (LSM) methods provide a means to identify brain areas that are strongly associated with specific symptoms. However, inner variations in LSM methods can yield different results. To address this, our study aimed to characterize the lesion-symptom mapping variability using three different LSM methods. Specifically, we sought to determine a lesion symptom core across LSM approaches enhancing the robustness of the analysis and removing potential spatial bias.
MATERIAL & METHODS: A cohort consisting of 35 patients with either right- or left-sided middle cerebral artery strokes were enrolled and evaluated using the NIHSS at 24 h post-stroke. Anatomical T1w MRI scans were also obtained 24 h post-stroke. Lesion masks were segmented manually and three distinctive LSM methods were implemented: ROI correlation-based, univariate, and multivariate approaches.
RESULTS: The results of the LSM analyses showed substantial spatial differences in the extension of each of the three lesion maps. However, upon overlaying all three lesion-symptom maps, a consistent lesion core emerged, corresponding to the territory associated with elevated NIHSS scores. This finding not only enhances the spatial accuracy of the lesion map but also underscores its clinical relevance.
CONCLUSION: This study underscores the significance of exploring complementary LSM approaches to investigate the association between brain lesions and stroke outcomes. By utilizing multiple methods, we can increase the robustness of our results, effectively addressing and neutralizing potential spatial bias introduced by each individual method. Such an approach holds promise for enhancing our understanding of stroke pathophysiology and optimizing patient care strategies.
Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) \<1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) \<1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
NRD135S.E1 as a potential treatment for moderate to severe painful diabetic peripheral neuropathy (PDPN). While the activity of NRD135S.E1 has been extensively studied, its molecular target is not known, though it does not appear to work through any of the opioid receptors or molecular pathways currently targeted by available analgesics. The best evidence suggests it may act, at least in part, through modulating the Lyn kinase signaling pathway In clinical studies, NRD135S.E1 has been well tolerated at all dose levels tested in single-dose (up to 1,200 mg) and repeat-dose regimens (up to 300 mg/day over 5 days or 150 mg over 3 weeks), and it has been shown to have predictable pharmacokinetics with dose-dependent increases in exposure.
Pharmaceutical preparations comprise at least one pharmaceutically active ingredient and substantially pure cellulose crystallite aggregates having an average level-off D.P. of from 15 to 375 anhydroglucose units and/or water- and/or organic slovent-insoluble derivatives thereof having a D.S. of at least 0.01 as at least a part of the carrier material.  Suitable derivatives include oxidation products containing aldehyde and/or carboxyl groups, ethers, esters, alkyl, aryl, aralkyl, substituted aralyl, carboxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, dialkylamino alkyl and aralkyl-oxyalkyl derivatives. The compositions may be in such forms as ointments, pastes, creams lotions, emulsions, suspensions, dispersions, solutions, tablets, pills, tablets, effervescent tablets, granules and coated tablets in which the cellulose crystallite aggregates may be comprised in a coating, especially a subcoat, the cellulosic material serving to supplement or replace one or more of the excipients conventionally used.  The pharmaceutically active material may be any which is compatible therewith, reference being made to analgesics, anti-infectives, antacids, anti-ulcerogenics, anti-histamines, hypnotics, sedatives, vitamins, stomachics, local anaesthetics, local irritants, astringents, fungicides and local antiseptics.  Specific examples relate to an antacid suspension comprising magnesium hydroxide; tablets comprising, (a) fish liver oil (Vitamins A & D) and (b) pentobarbital; ointments comprising, (a) benzoic and salicylic acids and (b) iodine; a calamine/ZnO2 lotion and a powder comprising medicinal mineral oil.  Specifications 970,111, 970,112 and 976,335 are referred to.
PURPOSE: To identify and synthesise the available evidence on the effect of mobility on social participation and quality of life (QoL) of wheelchairs (WC) on adults who use WC as their primary means of mobility.
MATERIALS AND METHODS: Systematic review undertaken in accordance with the Centre for Reviews and Dissemination Guidelines and registered in the PROSPERO International Prospective Register of Systematic reviews. Nine electronic databases (MEDLINE via PubMed, EMBASE, Cochrane Library, LILACS, CINAHL, PEDro, SCOPUS, Web of Science, and BVS ECOS) were searched with the following PICO eligibility criteria: (P) Population was individuals with mobility limitations that live in their community, aged 18 or older; (I) Intervention was mobility devices, such as manual and powered wheelchairs; (C) Comparators, not applied; (O) Outcome was factors that can be influenced by wheelchair use, such as: social participation, health-related quality of life and QOL. Critical appraisal of methodological quality of studies were undertaken.
RESULTS: A total of 18 studies were included. The proportion of studies evaluating the effects of mobility on participation was higher than to mobility on QoL. WC quality, device benefit (ease of repairs and maintenance), confidence using a WC and WC skills were key factors determining participation. The provision of WC according to the eight steps service proposed by the Word Health Organisation contributed to higher levels of physical health, WC satisfaction, hours using the WC and QoL enhancement.
CONCLUSION: Attention should be given to enhance WC service provision (with continuous service support) as well as professional continuing education.IMPLICATIONS FOR REHABILITATIONWheelchair technology is a key element in rehabilitation. Significant effort should be made to provide and maintain the wheelchair as a facilitator to participation. A great attention should be done to enhance wheelchair services as well as professional continuous education.Wheelchair skills are associated with participation and may be targeted in clinical intervention.
PROBLEM TO BE SOLVED: To provide an antiemetic composition for spray in the nasal cavity, capable of being easily administered and capable of providing rapid effects. SOLUTION: This antiemetic composition for the spray in the nasal cavity contains 2-8 pts.wt. ondansetron hydrochloride based on 100 pts.wt. base for the administration to the mucous membrane of the nasal cavity. The base consists of 70-85 wt.% water, 5-15 wt.% polyethylene glycol, 0.005-0.02 wt.% benzalkonium chloride, and 7-20 wt.% one kind of a solubilization promoter selected from the sodium salt of sulfobutyl ether-β-cyclodextrin, dimethyl-β- cyclodextrin, and 2-hydroxypropyl-β-cyclodextrin regulated so that the total may be 100 wt.%. The composition enables the nasal cavity administration of the antiemetic agent, and when the composition is administered in the nasal cavity, the rapid antiemetic effect is exhibited within 30 min after the administration.  The bioavailability of the ondansetron hydrochloride which is an active ingredient is improved, and a desirable effect is obtained even by the administration of a comparatively small amount thereof.
PURPOSE: A composition using CD137 gene is provided to reduce seizure symptom and to prevent apoptosis of nerve cells. CONSTITUTION: A composition for diagnosing brain diseases contains a probe or primer having complementary sequences to a nucleotide sequence of CD137 gene. The brain diseases include epilepsy, seize, Alzheimer's disease, or Parkinson's disease. A kit for diagnosing brain diseases contains the probe or primer. A microarray for diagnosing brain diseases contains the primer or probe. A method for screening a material for preventing or treating brain diseases comprises: a step of contacting a sample to cells containing CD137 genes or proteins; a step of measuring CD137 gene and protein expression level or CD137 protein activation level; and a step of determining the sample is a material for treating or preventing brain diseases in case that the CD137 gene and protein expression level or CD137 protein activation level is reduces.
The invention relates to a Chinese traditional medicine capsule for curing the cardio-cerebral vascular disease and the apoplexia sequelae. The invention consists of 24 components of astragalus root, rhizome of Sichuan lovage, red sage root, ledebouriella root, ginseng root, batryticated silkworm, panax pseudo-ginseng, root kudzuvine, Chinese angelica root, Chinese flowering quince, chyranthes root, dried leech, rhubarb, black nightshade, earth worm, fructus trichosanthis, black catechu, magnet, semen strychni, antler, rhodobryum giganteum, erigeron breviscapus, lilyturf root, and fruit orange magnoliavine. After being prepared, the 24 components are mixed, ground into powder and then filled in the num. 0 capsules. The invention has the advantages that one kind of medicine can cure a great variety of pathological symptoms, the curative ratio is high, the invention not only has the therapeutic effect, but also has the health protection effect, and the invention is economical and substantial. The products of the invention are mainly used to cure the diseases such as the coronary heart disease, the arrhythmia, the essential hypotension, the hypertension, the cerebral arteriosclerosis, the cerebral anoxia, the apoplexia sequelae and the hemiparalysis, etc.